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SUPPLEMENTARY NOTES
ABSTRACT
It is now well established that there is a preclinical period of rheumatoid arthritis (RA) development that is characterized by abnormalities of the immune system prior to the onset of the clinically apparent inflammatory joint disease that currently defines RA. The primary goal of this project is to investigate this preclinical period in order to understand two major factors: 1) how biomarker changes in preclinical RA can be used to accurately predict the future development of RA in currently asymptomatic individuals, and 2) to identify factors related to the pathogenesis of RA that can ultimately be targeted to prevent RA. This project has proposed to use a unique set of serum samples and clinical data available through the Department of Defense Serum Repository (DoDSR) to investigate the preclinical period of RA. During the first year of this project (30 Sep 2013 -29 Sep 2014 we have acquired the serums samples and data from the DoDSR, and performed initial biomarker testing.
SUBJECT TERMS
Prediction of future rheumatoid arthritis; pathogenesis of rheumatoid arthritis It is now well established that there is a preclinical period of rheumatoid arthritis (RA) development that is characterized by abnormalities of the immune system prior to the onset of the clinically apparent inflammatory joint disease that currently defines RA. The primary goal of this project is to investigate this preclinical period in order to understand two major factors: 1) how biomarker changes in preclinical RA can be used to accurately predict the future development of RA in currently asymptomatic individuals, and 2) to identify factors related to the pathogenesis of RA that can ultimately be targeted to prevent RA.
This project has proposed to use a unique set of serum samples and clinical data available through the Department of Defense Serum Repository (DoDSR) to investigate the preclinical period of RA.
As described below in more detail, during the first year of this project, we have acquired the serums samples and data from the DoDSR, and performed initial biomarker testing. Goal 2. Local and governmental IRB approvals, and HRPO approval, were obtained for this project.
KEYWORDS:
Goal 3. Research assistants were hired and trained for this project. Please see the 'Participation' section below for details of these individuals.
Goal 4. We performed serum sample testing for each of the following: -Anti-CCP2 using ELISA kits (Axis-Shield) and established methodologies.
-Anti-CCP3.1 using ELISA kits (INOVA) and established methodologies.
-Rheumatoid factor isotypes (A, G and M) using ELISA kits (INOVA) and established methodologies. -Samples for testing of ACPA arrays using bead-based array and established methodologies have been shipped to lab of co-investigators Drs William Robinson and Jeremy Sokolove. Completion of this testing was delayed due to delays in obtaining reagents; however, materials are obtained and testing will be complete by 30 Nov 2014.
To date to preserve the scientific integrity of the project, we are remaining blinded to subject status (e.g. RA case v. control), and full un-blinded analyses of these results are planned for years 2 and 3 of this project. However, in preliminary unblended analyses we have found that a substantial proportion of samples were positive for autoantibodies (see the Table immediately below) . Overall, these results demonstrate that the sample set obtained from the DoDSR will have sufficient autoantibody positivity and are adequate to accomplish the overall goal of the project which is to use biomarkers and other factors to develop a model to predict the likelihood and timing of future RA. This was performed in the lab of Drs Ted Mikuls and Geoffrey Thiele using established protocols. Full analyses of these results are planned for years 2 and 3 of this project.
What opportunities for training and professional development has the project provided?
In this initial phase of the project, activities did not include training and professional development. However, in years 2 and 3 of the project we expect that this project will allow for early career rheumatologists including fellows and junior faculty to participate in scientific research. During the next two years of the project, these activities will expand through more detailed analyses and publications, and additional personnel will be posted when they become known.
How were the results disseminated to communities of interest? Nothing to report because during this first year of the three-year project, our goals were to perform data and sample acquisition, and initial sample testing.
What do you plan to do during the next reporting period to accomplish the goals?
During the next two years of the project, we will complete sample testing, and then perform analyses as described in our Statement of Work.
IMPACT:
What was the impact on the development of the principal discipline(s) of the project? Nothing to report at this phase of the project.
What was the impact on other disciplines? Nothing to report at this phase of the project.
What was the impact on technology transfer? Nothing to report at this phase of the project.
What was the impact on society beyond science and technology? Nothing to report at this phase of the project.
CHANGES/PROBLEMS:
Changes in approach and reasons for change There have been no substantive changes in the overall approach. However, we had initially allocated a certain amount of funds to obtain the serum samples from the DoDSR; however, we needed fewer funds than anticipated. As of October 2014 we have therefore petitioned the DoD to use these remaining funds for additional testing of the serum samples; specifically to test for isotypes immunoglobulin (Ig) A, IgG and IgM to citrullinated proteins. We are currently awaiting a final decision from the DoD whether those funds will be available. We will update the SOW and other materials once this additional testing has been approved.
Actual or anticipated problems or delays and actions or plans to resolve them Due to the government shut-down and then funding cut-backs at the DoD level, the process of extracting data and serum samples from the DoDSR was delayed; however, we have obtained the samples and are on track to complete the proposed testing as outlined in the Statement of Work. Also, as mentioned above, there was a delay in obtaining reagents for 
